Celiac Drugs

Celiac Drugs Market Outlook

The global Celiac Drugs Market is projected to reach approximately USD 1.2 billion by 2035, with a significant compound annual growth rate (CAGR) of about 8.2% during the forecast period from 2025 to 2035. This growth can be attributed to the increasing prevalence of celiac disease, which affects a considerable portion of the global population, prompting the demand for effective therapeutic options. Additionally, the rising awareness and diagnosis of celiac disease are contributing to the growth of this market, as more individuals seek treatment to manage their symptoms and improve their quality of life. Enhanced research and development activities aimed at discovering new drugs and therapies are also driving market expansion. Furthermore, the growing trend of online pharmacies and telemedicine is making it more convenient for patients to access these medications, thereby propelling market growth.

Growth Factor of the Market

The growth of the Celiac Drugs Market is significantly influenced by several key factors. First, the increasing awareness and understanding of celiac disease among both healthcare providers and patients lead to earlier diagnosis and treatment. This is vital, as many individuals remain undiagnosed for years, suffering from various symptoms that severely affect their quality of life. Second, advancements in pharmaceutical research are yielding innovative drug formulations that target the underlying causes of celiac disease more effectively, which enhances patient compliance and therapeutic outcomes. Third, the expansion of healthcare infrastructure, particularly in developing regions, facilitates better access to healthcare services and, consequently, to medications for celiac disease. Additionally, the increasing trend of gluten-free diets has heightened the demand for gluten-digesting enzymes, spurring the development of specialized drugs that cater to this need. Lastly, the growing focus on personalized medicine allows healthcare providers to tailor treatments to individual patient profiles, further driving the market growth.

Key Highlights of the Market

• Projected market size of USD 1.2 billion by 2035 with an 8.2% CAGR from 2025 to 2035.
• Increasing incidence of celiac disease leading to heightened demand for therapeutic solutions.
• Growth in research and development efforts to create advanced medications for celiac disease management.
• Expansion of online pharmacies enhancing patient access to celiac drugs.
• Rising public awareness about gluten sensitivity and celiac disease driving market opportunities.

By Drug Type

Gluten Enzymes:

Gluten enzymes are gaining popularity as a significant drug type in the management of celiac disease. These enzymes, which aid in the digestion of gluten, help mitigate the adverse effects of accidental gluten ingestion. Patients who are diagnosed with celiac disease frequently struggle with managing their diets, leading to a potential for gluten exposure. Gluten enzymes serve as a therapeutic adjunct, allowing patients to enjoy a wider variety of foods without the accompanying symptoms. The rising consumer preference for gluten-free diets and the need for supplements that can enhance gluten digestion fuel the demand for these products. As awareness about gluten intolerance increases, the gluten enzyme market is expected to witness substantial growth during the forecast period.

Immunosuppressants:

Immunosuppressants are another critical category of drugs used in the treatment of celiac disease, particularly in severe cases where the immune response is overly aggressive. These medications help modulate the immune system's activity, preventing it from damaging the intestinal lining in response to gluten. The use of immunosuppressants is generally reserved for patients who do not respond adequately to traditional gluten-free dietary interventions. While they offer significant benefits in controlling symptoms and promoting intestinal healing, their use is often limited due to potential side effects and risks of infection. Nonetheless, the increasing recognition of the need for robust therapeutic solutions in managing celiac disease is likely to sustain the market for immunosuppressants.

Corticosteroids:

Corticosteroids are commonly utilized in the management of celiac disease, particularly for addressing severe inflammation and associated symptoms. These drugs act by reducing inflammation and suppressing the immune response, which is crucial in patients experiencing severe reactions to gluten. While corticosteroids are effective, they are typically recommended for short-term use due to the risk of long-term side effects, such as weight gain and increased susceptibility to infections. The market for corticosteroids in treating celiac disease is driven by the need for immediate symptom relief in acute cases. As clinicians seek to balance effective symptom management with the potential adverse effects of long-term corticosteroid use, this segment is expected to evolve as new therapeutic strategies emerge.

Anti-inflammatory Drugs:

Anti-inflammatory drugs play a significant role in the therapeutic landscape of celiac disease, as they help address the inflammation and discomfort associated with gluten sensitivity. These medications are often used in conjunction with dietary changes to provide relief from gastrointestinal symptoms. The demand for anti-inflammatory drugs is expected to rise as more patients seek effective management solutions for their celiac disease symptoms. The development of targeted therapies that reduce gastrointestinal inflammation without suppressing the entire immune system represents a promising area of research. As more evidence supporting the efficacy of these drugs in celiac disease accumulates, the anti-inflammatory drug segment is likely to experience considerable growth in the coming years.

Others:

The 'Others' segment encompasses various emerging therapies and experimental drugs that are currently under research and development for the treatment of celiac disease. This includes novel approaches such as vaccines aimed at inducing tolerance to gluten, as well as biologic therapies targeting specific immune pathways involved in celiac disease. As the understanding of celiac disease advances, the landscape of treatment options is expected to expand significantly. Research institutions and pharmaceutical companies are investing heavily in this area, driven by the need for comprehensive treatment strategies that go beyond dietary management. The success of these experimental therapies could potentially reshape the therapeutic options available to patients, leading to a transformation in the overall management of celiac disease.

By Route of Administration

Oral:

Oral administration is the most common route for celiac drugs, as it offers convenience and ease of use for patients. Most medications, including gluten enzymes and anti-inflammatory drugs, are formulated for oral intake, making them accessible for daily use. This method allows patients to integrate their treatment seamlessly into their daily routines, improving adherence to prescribed therapies. The oral route is particularly advantageous for chronic conditions like celiac disease, where long-term treatment is necessary. As consumer preferences shift toward more user-friendly medication formats, the oral segment is expected to maintain a dominant position in the celiac drugs market.

Intravenous:

Intravenous (IV) administration is primarily used in cases where rapid therapeutic action is required, particularly in patients with severe symptoms or complications related to celiac disease. This method ensures immediate bioavailability and is often employed in hospital settings for acute management. While IV administration may not be the first-line approach for most celiac disease treatments, it plays a crucial role in emergency situations where oral medications are ineffective. The growth of the IV segment is driven by the increasing recognition of the need for comprehensive care for patients experiencing severe manifestations of celiac disease.

Subcutaneous:

Subcutaneous administration is gaining traction as an alternative route for delivering certain therapies, especially in the context of biologics or long-acting medications. This method allows patients to self-administer their treatment at home, enhancing convenience and adherence. Subcutaneous injections can be particularly beneficial in the management of celiac disease, where regular treatment is essential for maintaining health. As new subcutaneous formulations of existing therapies are developed, this route is expected to see growth, providing an additional option for patients who prefer not to take oral medications.

Rectal:

Rectal administration is typically reserved for specific treatments aimed at addressing localized symptoms, such as severe diarrhea or rectal inflammation associated with celiac disease. Although this route is less commonly utilized compared to oral or intravenous methods, it can be effective in managing acute symptoms that may not respond to systemic therapies. The rectal route offers direct delivery to the affected area, providing targeted relief. As researchers continue to explore various administration routes, rectal formulations may see a niche market among patients who require localized treatment options.

Others:

The 'Others' category includes less conventional routes of administration that may arise as research into celiac disease therapies advances. Innovations such as transdermal patches or inhalable formulations could potentially provide alternative options for patients, enhancing drug delivery and compliance. Although these routes are currently not mainstream in the treatment of celiac disease, the ongoing focus on patient-centered care and the need for more effective administration methods may lead to the exploration of these alternatives. As the pharmaceutical landscape evolves, the potential for new routes of administration represents an exciting frontier in the management of celiac disease.

By Distribution Channel

Hospitals:

Hospitals are a primary distribution channel for celiac drugs, especially for patients requiring immediate care and specialized treatments. In a hospital setting, healthcare providers can prescribe medications based on the severity of symptoms and ensure patients receive appropriate support. The integration of multidisciplinary care teams, including dietitians and specialists in gastroenterology, enhances the overall management of celiac disease within hospitals. As the number of patients diagnosed with celiac disease continues to rise, hospitals are likely to play a pivotal role in the administration of both acute and long-term therapies, contributing significantly to the market's growth.

Retail Pharmacies:

Retail pharmacies serve as a vital distribution channel for celiac drugs, providing accessibility and convenience for patients seeking their medications. With the growing awareness of celiac disease and the increasing demand for specialty dietary supplements like gluten enzymes, retail pharmacies are expanding their inventory to include these products. The ability for patients to obtain prescriptions and over-the-counter gluten management products at their local pharmacy fosters better adherence to treatment plans. This channel is expected to witness continuous growth as patients become more proactive in managing their condition and seeking available therapeutic options.

Online Pharmacies:

Online pharmacies have emerged as an increasingly popular distribution channel, especially in the wake of the COVID-19 pandemic, which accelerated the shift toward digital healthcare solutions. The convenience of ordering medications from home, combined with the availability of a wide range of celiac drugs, positions online pharmacies as a critical player in the market. Patients can access specialized medications, such as gluten enzymes and immunosuppressants, with ease, often benefiting from competitive pricing and home delivery options. As digital healthcare continues to evolve, the online pharmacy segment is expected to see substantial growth, catering to the needs of a tech-savvy patient population.

Speciality Clinics:

Speciality clinics focusing on gastrointestinal health and celiac disease management are crucial distribution channels for celiac drugs. These clinics often provide comprehensive care, including diagnostic testing, dietary counseling, and personalized treatment plans. Patients who frequent these clinics benefit from tailored therapies that address their specific symptoms and health needs. As more individuals seek specialized care for celiac disease, the presence of these clinics is expected to increase, thereby contributing to the overall market growth by facilitating access to effective medications.

Others:

The 'Others' segment encompasses various distribution channels, including health food stores, nutritional supplement retailers, and direct-to-consumer brands that offer celiac drugs and dietary supplements. These channels cater to a niche market of health-conscious consumers who prioritize gluten-free living and seek products that support their dietary restrictions. As the demand for gluten-free products grows, alternative distribution channels are likely to become more established, providing greater access to a wider range of celiac drugs and supporting the overall market's expansion.

By User

Hospitals:

Hospitals serve as a primary user of celiac drugs, especially in acute care scenarios where patients experience severe symptoms or complications resulting from celiac disease. The integration of specialized teams, including gastroenterologists and nutritionists, allows hospitals to provide comprehensive management for patients. As the prevalence of celiac disease increases, hospitals can expect a growing need for effective treatments, driving demand for various therapeutic options. The ability to monitor patients closely during their hospital stay further enhances the effectiveness of drug administration, ensuring optimal patient outcomes.

Clinics:

Clinics dedicated to gastrointestinal health are integral users of celiac drugs, providing ongoing management and support for patients with celiac disease. These facilities often conduct diagnostic testing, educate patients about dietary restrictions, and prescribe relevant medications. As awareness of celiac disease continues to grow, clinics are becoming increasingly important in the treatment landscape, enabling early diagnosis and timely intervention. The trend toward patient-centered care within clinics fosters a supportive environment where patients can receive tailored therapies, further propelling the demand for celiac drugs.

Ambulatory Surgical Centers:

Ambulatory surgical centers (ASCs) represent an emerging user category for celiac drugs, particularly in cases requiring surgical intervention for complications related to celiac disease. These facilities provide efficient, outpatient care, allowing patients to undergo procedures without the need for extended hospital stays. As surgical options for managing celiac disease-related issues become more prevalent, ASCs will play a crucial role in delivering the necessary medications and post-operative care for patients. The growth of this segment is indicative of the evolving landscape of celiac disease management and the increasing need for integrated care solutions.

Homecare:

Homecare represents a crucial user segment for celiac drugs, as more patients seek to manage their condition independently. This shift toward homecare is driven by the desire for convenience and the ability to engage in self-management strategies. Patients can utilize gluten enzymes and other medications in the comfort of their homes, promoting adherence to treatment regimens. Additionally, the increasing availability of telehealth services enables healthcare providers to offer ongoing support and monitoring for patients receiving homecare. As the trend toward personalized medicine continues, the homecare segment is expected to expand, providing patients with greater autonomy in managing their celiac disease.

By Region

The North America region holds a significant share of the global Celiac Drugs Market, accounting for approximately 45% of the total market value. This dominance can be attributed to the high prevalence of celiac disease and the growing awareness among healthcare providers and patients alike. The presence of advanced healthcare infrastructure and a strong emphasis on research and development in the pharmaceutical sector further bolster market growth in this region. North America is also witnessing a rise in the demand for gluten-free products and therapies, leading to the development of innovative treatment options. The region is expected to maintain its leading position, with a projected CAGR of 8.5% through 2035.

In Europe, the Celiac Drugs Market is experiencing robust growth, driven by the increasing incidence of celiac disease and a rising population awareness of gluten-related disorders. Europe is expected to account for approximately 30% of the global market by 2035. The region's strong regulatory framework for pharmaceutical products and a growing number of specialty clinics focused on celiac disease management are contributing factors to this growth. Moreover, the rising adoption of gluten-free diets and the availability of novel therapeutic options are supporting the market's upward trajectory. As healthcare providers in Europe continue to prioritize patient-centered care, the demand for effective celiac drugs is anticipated to rise, ensuring a healthy growth outlook.

Opportunities

As the global Celiac Drugs Market evolves, numerous opportunities are emerging that stakeholders can capitalize on. One significant opportunity lies in the development of novel therapies that target the underlying mechanisms of celiac disease. Research efforts focused on gluten immunotherapy and biologics aimed at inducing tolerance to gluten could revolutionize treatment options for patients. If successful, these therapies may provide a long-term solution for managing celiac disease, reducing reliance on strict dietary restrictions. Furthermore, as the awareness of gluten sensitivity grows, there is an expanding market for dietary supplements and adjunctive therapies, such as gluten-digesting enzymes, that can improve patients' quality of life. Companies that invest in research and development for these innovative products are well-positioned to capture a significant share of the emerging market.

Another opportunity exists in expanding access to celiac drugs through digital platforms and telemedicine. As patients increasingly seek convenience and flexibility in managing their health, online pharmacies and telehealth services offer a way to bridge the gap between patients and healthcare providers. The growing trend of remote consultations and home delivery of medications allows patients to obtain necessary treatments without the barriers associated with traditional healthcare settings. This strategic shift can enhance patient engagement and adherence, ultimately resulting in better health outcomes. Companies that embrace these digital transformations and develop patient-centric approaches will likely thrive in the competitive landscape of the celiac drugs market.

Threats

Despite the promising outlook for the Celiac Drugs Market, there are various threats that could hinder its growth. One major concern is the potential for stringent regulatory changes affecting the approval and commercialization of new therapies. Regulatory bodies' evolving standards for safety and efficacy testing could delay the introduction of innovative treatments, impacting market dynamics. Additionally, market competition may intensify as more pharmaceutical companies enter the space, leading to price pressures and potential challenges in maintaining profit margins. The presence of generic alternatives may also impact the revenues of branded medications, making it critical for companies to differentiate their products through unique value propositions.

Moreover, the increasing prevalence of counterfeit medications poses a significant risk to the Celiac Drugs Market. As the demand for effective therapies rises, the likelihood of counterfeit products entering the market also increases. Counterfeit medications can lead to compromised patient safety and efficacy, creating distrust among consumers and healthcare providers. The vigilance of regulatory authorities and the implementation of robust supply chain measures are critical to mitigating this threat. Furthermore, ongoing education and awareness campaigns are necessary to inform patients about the risks associated with counterfeit drugs, ensuring they can make informed decisions regarding their treatment options.

Competitor Outlook

• AbbVie Inc.
• TheraCel, Inc.
• Glutenase, Inc.
• Alvine Pharmaceuticals, Inc.
• Sanofi S.A.
• Generex Biotechnology Corporation
• ImmusanT, Inc.
• Provention Bio, Inc.
• Celimmune LLC
• Takeda Pharmaceutical Company Limited
• Merck & Co., Inc.
• Novartis International AG
• Pfizer Inc.
• Regeneron Pharmaceuticals, Inc.
• Gilead Sciences, Inc.

The competitive landscape of the Celiac Drugs Market is characterized by a diverse array of players ranging from established pharmaceutical giants to innovative startups. Major corporations like AbbVie, Takeda, and Sanofi have made significant investments in research and development to create effective therapies for celiac disease, leveraging their extensive resources and expertise. These companies focus on developing a portfolio of drugs that address various aspects of celiac disease management, catering to different patient needs. Furthermore, collaboration between biotech firms and pharmaceutical companies is on the rise as they seek to combine their strengths to accelerate drug development processes and reduce time to market.

Smaller companies, including ImmusanT and Alvine Pharmaceuticals, are contributing to the innovation landscape by exploring novel approaches to celiac disease treatment. These firms are often focused on developing specific therapies such as gluten immunotherapy or unique drug formulations that provide targeted relief for patients. Their agility and dedication to addressing unmet medical needs position them well to disrupt the market and challenge larger competitors. As scientific advancements continue to emerge, new entrants may stimulate competition, driving further innovation and potentially leading to better treatment options for patients suffering from celiac disease.

Key players in the market also emphasize a patient-centric approach, striving to understand the needs and preferences of patients with celiac disease. Companies like Gilead and Pfizer are investing in educational initiatives and resources to support patients in managing their condition effectively. This commitment to patient engagement enhances brand loyalty and fosters relationships with healthcare providers, ultimately translating into market success. By prioritizing patient outcomes and leveraging their research capabilities, leading companies in the Celiac Drugs Market aim to position themselves as trusted partners in the journey toward effective celiac disease management.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 AbbVie Inc.
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 Pfizer Inc.
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 Sanofi S.A.
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 Celimmune LLC
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 ImmusanT, Inc.
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 TheraCel, Inc.
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Glutenase, Inc.
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Merck & Co., Inc.
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Provention Bio, Inc.
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Gilead Sciences, Inc.
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Novartis International AG
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Alvine Pharmaceuticals, Inc.
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Regeneron Pharmaceuticals, Inc.
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Generex Biotechnology Corporation
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Takeda Pharmaceutical Company Limited
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Celiac Drugs Market, By User
    • 6.1.1 Hospitals
    • 6.1.2 Clinics
    • 6.1.3 Ambulatory Surgical Centers
    • 6.1.4 Homecare
  • 6.2 Celiac Drugs Market, By Drug Type
    • 6.2.1 Gluten Enzymes
    • 6.2.2 Immunosuppressants
    • 6.2.3 Corticosteroids
    • 6.2.4 Anti-inflammatory Drugs
    • 6.2.5 Others
  • 6.3 Celiac Drugs Market, By Distribution Channel
    • 6.3.1 Hospitals
    • 6.3.2 Retail Pharmacies
    • 6.3.3 Online Pharmacies
    • 6.3.4 Speciality Clinics
    • 6.3.5 Others
  • 6.4 Celiac Drugs Market, By Route of Administration
    • 6.4.1 Oral
    • 6.4.2 Intravenous
    • 6.4.3 Subcutaneous
    • 6.4.4 Rectal
    • 6.4.5 Others

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Celiac Drugs Market by Region
  • 10.3 Asia Pacific - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 India
      • 10.3.1.2 China
      • 10.3.1.3 Japan
      • 10.3.1.4 South Korea
  • 10.4 Latin America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 Brazil
      • 10.4.1.2 Argentina
      • 10.4.1.3 Mexico
  • 10.5 North America - Market Analysis
    • 10.5.1 By Country
      • 10.5.1.1 USA
      • 10.5.1.2 Canada
  • 10.6 Middle East & Africa - Market Analysis
    • 10.6.1 By Country
      • 10.6.1.1 Middle East
      • 10.6.1.2 Africa

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Celiac Drugs market is categorized based on

By Drug Type

• Gluten Enzymes
• Immunosuppressants
• Corticosteroids
• Anti-inflammatory Drugs
• Others

By Route of Administration

• Oral
• Intravenous
• Subcutaneous
• Rectal
• Others

By Distribution Channel

• Hospitals
• Retail Pharmacies
• Online Pharmacies
• Speciality Clinics
• Others

By User

• Hospitals
• Clinics
• Ambulatory Surgical Centers
• Homecare

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East
• Africa

Key Players

• AbbVie Inc.
• TheraCel, Inc.
• Glutenase, Inc.
• Alvine Pharmaceuticals, Inc.
• Sanofi S.A.
• Generex Biotechnology Corporation
• ImmusanT, Inc.
• Provention Bio, Inc.
• Celimmune LLC
• Takeda Pharmaceutical Company Limited
• Merck & Co., Inc.
• Novartis International AG
• Pfizer Inc.
• Regeneron Pharmaceuticals, Inc.
• Gilead Sciences, Inc.